As part of the Revised National Tuberculosis Control Program (RNTCP), Union Health Minister J P Nadda launched Bedaquiline - new anti-TB drug for Drug Resistant TB and inducted over 500 Cartridge Based Nucleic Acid Amplification Test (CBNAAT) machines.
The CBNAAT is a revolutionary rapid molecular test which detects Mycobacterium tuberculosis and rifampicin drug resistance, simultaneously.
The test is fully automated and provides results within two hours. It is a highly sensitive diagnostic tool and can be used in remote and rural areas without sophisticated infrastructure or specialized training.
"With the availability of these additional 500 machines, access to rapid quality assured diagnosis of DR TB and TB will be ensured in all the districts of India either directly or through a linkage by specimen transport mechanism.
More From This Section
"Additionally, the programme will be able to use this highly sensitive state-of-art technology for diagnosis of TB among key populations like children, PLHIV and extra pulmonary TB patients," said Nadda at an event "Unite to End TB: Fast Tracking access to quality diagnosis and treatment".
"The Fight against TB is continuous process and we have been fighting against the disease for a long time. The Revised National Tuberculosis Control Program (RNTCP) was started in 1997 and saw ups and downs, strategising and destrategising. In the course of time sometimes, the attention gets diluted and diverted and we have to stay focused.
(REOPENS DEL27)
The Health Minister also released the TB India 2016
Annual Report and the Technical and Operational Guidelines for TB Control in India 2016.
The comprehensive set of guidelines are for management of all forms of TB, including drug resistant TB and strategies for intensified case finding; adherence of more patient centric approaches; and single-window care for patients suffering from HIV and TB.
A new radio campaign with TB ambassador Amitabh Bachchan and social media campaign, were also launched at the event.
Nadda also launched the 'Third line ART programme for People Living with HIV'. The life-saving third line ART costs nearly Rs 1.18 lakh per patient per year.
Providing these free would not only safe lives but improve socioeconomic conditions of the patients. This initiative brings India's ART programme at par with programmes in the developed countries.
India and Indonesia (23 and 10 per cent of the global total) have the largest number of TB cases.